Table 2.

Gene-expression-based biomarkers for ICIs response in NSCLC.

Biomarker	Method	Key Finding
HNRNPA2B1, IGF2BP2, NSUN4, ALYREF	Public datasets	ADC patients classified as high risk presented improved outcomes and were associated with ICI efficacy [80].
Immune-score	Public datasets	Classification based on the immune-score was correlated with improved outcomes in ICI-treated patients [77].
KAT2B	Public datasets	Low KAT2B is correlated with immune infiltration and high TMB and associated with unfavorable outcomes in ICI-treated ADC patients [75].
MAP1A/1B/1S/4/6/7D1 /7D3	Public datasets/RT-qPCR	Expression of the MAP gene-set is correlated with the immunophenoscore, a predictor of response of PD-1 blockers and CTLA-4 [74].
TCR co-expression	Public datasets	High TCR co-expression indicated better ICI response and improved OS and PFS [76].

ADC—adenocarcinoma; ICI—immune checkpoint inhibitor; TMB—tumor mutation burden; RT-qPCR—reverse transcriptase quantitative polymerase chain reaction; PD-1—programmed cell death protein 1; CTLA-4—cytotoxic T-lymphocyte-associated protein 4; TCR—T cell receptor; OS—overall survival; PFS—progression-free survival.